Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit

[1]  W. Thies,et al.  The draft “National Plan” to address Alzheimer's disease - National Alzheimer's Project Act (NAPA) , 2012, Alzheimer's & Dementia.

[2]  Mark E. Schmidt,et al.  The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception , 2012, Alzheimer's & Dementia.

[3]  Leslie M. Shaw,et al.  Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative , 2012, Alzheimer's & Dementia.

[4]  Giovanni B. Frisoni,et al.  The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers , 2011, Alzheimer's & Dementia.

[5]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[6]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[7]  Nick C Fox,et al.  The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[8]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[9]  M. Weiner,et al.  Developing a global strategy to prevent Alzheimer’s disease: Leon Thal Symposium 2010 , 2011, Alzheimer's & Dementia.

[10]  Nick C Fox,et al.  Revising the definition of Alzheimer's disease: a new lexicon , 2010, The Lancet Neurology.

[11]  S. Borson,et al.  Comorbidity in aging and dementia: scales differ, and the difference matters. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[12]  D. Sargent,et al.  Biomarkers and surrogate end points—the challenge of statistical validation , 2010, Nature Reviews Clinical Oncology.

[13]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[14]  S. Borson.  Cognition, aging, and disabilities: conceptual issues. , 2010, Physical medicine and rehabilitation clinics of North America.

[15]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[16]  Christos Davatzikos,et al.  Design of comprehensive Alzheimer's disease centers to address unmet national needs , 2010, Alzheimer's & Dementia.

[17]  Oscar L. Lopez,et al.  Developing a national strategy to prevent dementia: Leon Thal Symposium 2009 , 2010, Alzheimer's & Dementia.

[18]  G. Schellenberg,et al.  Creating a transatlantic research enterprise for preventing Alzheimer's disease , 2009, Alzheimer's & Dementia.

[19]  Z. Khachaturian.  A roadmap for the prevention of dementia II: Leon Thal Symposium 2008 , 2009, Alzheimer's & Dementia.

[20]  J. Greene.  Prescribing by Numbers: Drugs and the Definition of Disease , 2007 .

[21]  L. Thal,et al.  The Nevada Vital Aging Initiative: A private-public partnership to study early predictors of dementia , 2007, Alzheimer's & Dementia.

[22]  Vijaya L. Melnick,et al.  Alzheimer’s Dementia , 1985, Contemporary Issues in Biomedicine, Ethics, and Society.